Collegium Pharmaceutical Inc (COLL)
Return on equity (ROE)
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Net income | US$ in thousands | 69,190 | 48,155 | -25,002 | 71,517 | 26,752 |
| Total stockholders’ equity | US$ in thousands | 228,842 | 195,431 | 194,842 | 202,928 | 186,031 |
| ROE | 30.23% | 24.64% | -12.83% | 35.24% | 14.38% |
December 31, 2024 calculation
ROE = Net income ÷ Total stockholders’ equity
= $69,190K ÷ $228,842K
= 30.23%
Collegium Pharmaceutical Inc's return on equity (ROE) has shown notable fluctuations over the past five years. The ROE stood at 14.38% on December 31, 2020, indicating a moderate level of profitability relative to shareholder equity. Subsequently, the ROE significantly improved to 35.24% by December 31, 2021, reflecting a considerable increase in profitability and efficiency in generating returns for shareholders.
However, there was a sharp decline in ROE to -12.83% by December 31, 2022, indicating an unprofitable period where the company's net income was insufficient to cover shareholders' equity. Collegium Pharmaceutical Inc managed to rebound in the following year, with an ROE of 24.64% by December 31, 2023, showing a positive turnaround in profitability.
By December 31, 2024, the ROE further improved to 30.23%, suggesting that Collegium Pharmaceutical Inc continued to enhance its ability to generate profits from the shareholders' equity invested in the company. Overall, the recent trend in ROE indicates that Collegium Pharmaceutical Inc has been successful in optimizing its profitability and delivering value to its shareholders, albeit with some fluctuations along the way.
Peer comparison
Dec 31, 2024